QDEL · QuidelOrtho Corp

QuidelOrtho has entered a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. (Lifotronic Technology Co., Ltd., stock code: 688389), to expand QuidelOrtho's global immunoassay portfolio and accelerate customer access to scalable, high quality, cost-efficient solutions across select markets outside the United States. The agreement provides QuidelOrtho access to multiple high-throughput and low-to-mid volume immunoassay analyzer platforms, each supported by a broad menu of assays spanning routine and specialty testing. The collaboration is expected to expand QuidelOrtho's immunoassay menu with more than 25 new assays on these systems that are not currently available on the VITROS system, within a total menu of over 70 assays on these new partner platforms. These additions are planned to increase QuidelOrtho's ability to compete for full-menu tenders and serve a wider range of laboratory settings, from smaller laboratories seeking low-volume solutions to larger,

QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the fourth quarter and full-year ended December 28, 2025. "In 2025, we transitioned from COVID-driven volatility to a more durable, diversified diagnostics business," said Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho. "Our Labs, Immunohematology and Cardiac businesses delivered consistent growth, while cost-savings initiatives drove meaningful margin expansion. As a result, we are well positioned to generate substantially stronger free cash flow in 2026, which we believe more accurately reflects the earnings power of our business." Key Fourth Quarter 2025 Results: (all comparisons are to the prior year period) Total revenue was $724 million, as reported Non-respiratory revenue of $600 million; excluding Donor Screening 1 , non-respiratory revenue grew 7% in constant currency. Labs revenue grew 8% as

QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho") received the Excellence Services Label for its Customer and Technical Services in EMEA, awarded by the independent association Esprit de Service France, and in accordance with the international standard ISO 23592, a global framework for designing and delivering outstanding customer experiences. QuidelOrtho is the first medical device company to receive this distinction. QuidelOrtho also won a Gold Stevie Award in the Customer Service Success category and a Bronze Stevie Award in the AI & Tech Focused Digital Transformation Team of the Year category in the 20th annual Stevie Awards for Sales & Customer Service. These awards underscore the customer experience at QuidelOrtho, which is designed to be predictive, connected, intelligent and grounded in the QuidelOrthoCQ™ Philosophy of turning intelligence and ease into care customers can feel. "These 2026 recognitions are a testament to the passion and discipline of our teams

QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released episode 55 of its Science Bytes podcast, featuring Michelle Mullens, Global Portfolio Marketing Manager for Transfusion Medicine. With decades of experience in blood banking and immunohematology, Mullens shares insights into the pressures on today's blood supply and the importance of consistent donor engagement. Key insights: Everyday and climate-driven emergencies strain supply: Routine trauma, traffic injuries and increasingly frequent weather events create unpredictable demand for blood products Universal types face rising pressure: Growth in prehospital low-titer whole blood programs accelerates consumption of O-type units, requiring more targeted donor recruitment and precise inventory management Automation strengthens resilience: Standardized, high-throughput immunohematology platforms enhance safety, ensure operational continuity during surges and enable staff to focus on complex cases

As a result of a recent research report regarding the potential for adoption of a dry chemistry Volume-Based Procurement (VBP) program in China, QuidelOrtho Corporation (the “Company”) is providing the following information: Currently, the Company’s business in China represents approximately 12% of total Company revenue. The Jiangxi Provincial Health Security Administration (HSA) stated that it will “explore launching national centralized procurement for dry chemistry (biochemical) test strips.”1 It is our understanding that there is no detailed proposal or plan for such a process currently. We have no indication that the Company’s products will be included in such a program, nor do we have any details on plans for implementation. Given the typical timing of the HSA and the National Healthcare Security Administration (NHSA) review and approval process, the Company does not expect to see implementation of any proposed JiangXi VBP program until at least late 2026. Any business impact on

QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, announced today that it will report its financial results for the fourth quarter and full year 2025 ended December 28, 2025, after the market close on Wednesday, February 11, 2026. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the "Events & Presentations" section of the "Investor Relations" page of the Company's website at https://ir.quidelortho.com . Presentation materials will also be posted to the "Events & Presentations" section of the "Investor Relations" page of the Company's website at the time of the call. Those unable to access the webcast may join the call via phone by dialing 833-470-1428 (domestic) or +1 929-526-1599 (international) and entering Conference ID number 690468. A replay of the